National Cancer Institute Home at the National Institutes of Health |
Please wait while this form is being loaded....
The Applied Research Program Web site is no longer maintained. ARP's former staff have moved to the new Healthcare Delivery Research Program, the Behavioral Research Program, or the Epidemiology & Genomics Research Program, and the content from this Web site is being moved to one of those sites as appropriate. Please update your links and bookmarks!

Publication Abstract

Authors: Baxi SS, O'Neill C, Sherman EJ, Atoria CL, Lee NY, Pfister DG, Elkin EB

Title: Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab.

Journal: Head Neck :-

Date: 2014 Dec 22

Abstract: Background: Cetuximab was approved for use in chemoradiation (CTRT) for locally-advanced head and neck squamous cell carcinoma (HNSCC) in 2006. Methods: Among 3,705 patients with locally-advanced HNSCC identified in the linked Surveillance Epidemiology and End Results (SEER)-Medicare database, we assessed treatment trends including surgery, RT, CTRT and specific agents used in CTRT. We examined the influence of demographic and clinical characteristics on the likelihood of receiving CTRT before and after 2006. Results: Chemoradiation use increased from 29% of patients diagnosed in 2001 to 61% in 2009 (p<0.0001). Compared to prior to 2006, neither age nor comorbidity score was associated with receipt of CTRT after 2006. Platinum combinations were the most commonly used concurrent chemotherapies before 2006, but since then cetuximab has become the most commonly used agent. Conclusions: The use of CTRT has increased substantially and cetuximab may have increased CTRT use, especially in older and sicker patients. This article is protected by copyright. All rights reserved.

Last Modified: 03 Sep 2013